Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment

NCT03060512 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03060512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
March 2, 2017
Completion date
August 23, 2017
Enrollment
276 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

opioid induced constipation